Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies
Antioxidants · 27.05.2023 · 12 (6) · 1163
DOI: 10.3390/antiox12061163 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, erschienen am 27.05.2023. Verfasst von Tianzheng Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Consortium for Health and Military Performance, Department of Military and Emergency Medicine, F. Edward Hébert School of Medicine, Uniformed Service…. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense (DoD) the Defense Health Program, U.S. Department of Defense (DoD)’s Defense Health Program.
Abstract (Originalsprache)
Mitochondrial fission is a crucial process in maintaining metabolic homeostasis in normal physiology and under conditions of stress. Its dysregulation has been associated with several metabolic diseases, including, but not limited to, obesity, type 2 diabetes (T2DM), and cardiovascular diseases. Reactive oxygen species (ROS) serve a vital role in the genesis of these conditions, and mitochondria are both the main sites of ROS production and the primary targets of ROS. In this review, we explore the physiological and pathological roles of mitochondrial fission, its regulation by dynamin-related protein 1 (Drp1), and the interplay between ROS and mitochondria in health and metabolic diseases. We also discuss the potential therapeutic strategies of targeting mitochondrial fission through antioxidant treatments for ROS-induced conditions, including the effects of lifestyle interventions, dietary supplements, and chemicals, such as mitochondrial division inhibitor-1 (Mdivi-1) and other mitochondrial fission inhibitors, as well as certain commonly used drugs for metabolic diseases. This review highlights the importance of understanding the role of mitochondrial fission in health and metabolic diseases, and the potential of targeting mitochondrial fission as a therapeutic approach to protecting against these conditions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Consortium for Health and Military Performance, Department of Military and Emergency Medicine, F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, MD 20814, USA.
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA.
- Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
- Department of Pathology, F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, MD 20814, USA.
- Center for the Study of Traumatic Stress, Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
ORCID-Profile: Li Wang, Patricia A Deuster
Förderung
- U.S. Department of Defense (DoD) the Defense Health Program
- U.S. Department of Defense (DoD)’s Defense Health Program
Zitieren
APA
Yu, T., Wang, L., Zhang, L., & Deuster, P. A. (2023). Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies. Antioxidants. https://doi.org/10.3390/antiox12061163
Vancouver
Yu T, Wang L, Zhang L, Deuster PA. Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies. Antioxidants. 2023. doi:10.3390/antiox12061163
BibTeX
@article{Yu2023,
author = {Yu, Tianzheng and Wang, Li and Zhang, Lei and Deuster, Patricia A},
title = {Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies},
journal = {Antioxidants},
year = {2023},
doi = {10.3390/antiox12061163}
}
EUVIMED